Pacific Biomarkers, Inc. to Exhibit at 20th Annual Partnerships in Clinical Trials Conference in Phoenix on March 30 - April 1

SEATTLE, WA--(Marketwire - March 22, 2011) - Pacific Biomarkers, Inc. (PBI) (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, will be exhibiting at the 20th Annual Partnerships in Clinical Trials Conference to be held at the Phoenix Convention Center in Phoenix, Arizona on March 30 - April 1.

The Partnerships in Clinical Trials Conference is an industry meeting place where face-to-face networking, practical case studies, hands-on workshops and roundtable discussions help meet the trial needs of clinical operations and outsourcing executives. The 2011 conference is expected to attract over 2,000 clinical and business professionals, 400 sponsor and provider organizations, 200 exhibitors with trial solutions, and 150 pharma, biotech and provider expert perspectives.

Ron Helm, PBI’s Chairman and Chief Executive Officer, said, “Exhibiting at the Partnerships in Clinical Trials Conference is a fantastic way of raising awareness of PBI to a large and influential cross-section of the clinical trials community. Our exhibit will spotlight the full range of PBI’s services and our capacity to facilitate a wide range of trials.”

For more information about the Partnerships in Clinical Trials Conference, please visit: www.clinicaltrialpartnerships.com

About Pacific Biomarkers, Inc. (PBI)
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI’s clients include many of the world’s largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, cell-based assay testing and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol “PBMC.” For more information about PBI, visit the company’s web site at www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release includes forward-looking statements including, but not limited to, the following: results of business development activities; future growth; and the viability and acceptance of the Company’s biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company’s ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company’s ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2010).